Femasys Reports Q3 2026 Financials and Announces $30 Million Financing

Femasys Inc. (NASDAQ: FEMY) released its financial results for the quarter ended September 30, 2026, alongside a corporate update on November 13, 2026. The company reported a net loss of $4,564,815 for the third quarter of 2026, or ($0.53) per share, compared to a net loss of $4,194,821, or ($2.05) per share, in the prior year period.

For the nine months ended September 30, 2026, the company recorded a net loss of $8,187,810, or ($1.59) per share, significantly narrowing compared to a net loss of $14,677,582, or ($9.25) per share, in the same period of 2025. The company reported cash and cash equivalents of approximately $23.9 million as of September 30, 2026, with an accumulated deficit of approximately $154.0 million.

Regarding sales, the company reported a slight increase in U.S. sales to $347,039 in 2026 from $336,594 in 2025. However, overall sales decreased by 44.5% to $404,597 in the third quarter of 2026 from $729,394 in the prior year. The company noted that this overall decline was anticipated and reflects the timing of international FemBloc orders, consistent with distributors’ bulk-ordering practices.

In a significant corporate development, Femasys announced the completion of a $30 million private placement. The company stated that the total proceeds could reach up to $85 million if all warrants are fully exercised. The company intends to use these funds to build out its U.S. commercial team and to finance the FemBloc pivotal trial to support U.S. approval.

On the product development front, Femasys highlighted progress with its FemaSeed fertility portfolio. The company announced partnerships with UNC Health and Minnesota Women’s Care to introduce the portfolio across OB/GYN practice locations, as well as a partnership with CapexMD to expand patient access through financing solutions. Additionally, the company reported that the number of actively enrolling sites in the FINALE trial for FemBloc doubled to twelve sites, and the company received FDA approval of the modular premarket approval (PMA) submission approach.